Abstract
Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 28-36 |
| Number of pages | 9 |
| Journal | American Journal of Kidney Diseases |
| Volume | 43 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2004 |
Fingerprint
Keywords
- Antiphospholipid (aPL) antibodies
- Arterial hypertension
- Chronic renal insufficiency
- Fetal loss
- Lupus nephritis
- Systemic lupus erythematosus (SLE)
- Thrombosis
ASJC Scopus subject areas
- Nephrology
Cite this
Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis. / Moroni, Gabriella; Ventura, Donatella; Riva, Paola; Panzeri, Paola; Quaglini, Silvana; Banfi, Giovanni; Simonini, Paola; Bader, Rossella; Meroni, Pier Luigi; Ponticelli, Claudio.
In: American Journal of Kidney Diseases, Vol. 43, No. 1, 01.2004, p. 28-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis
AU - Moroni, Gabriella
AU - Ventura, Donatella
AU - Riva, Paola
AU - Panzeri, Paola
AU - Quaglini, Silvana
AU - Banfi, Giovanni
AU - Simonini, Paola
AU - Bader, Rossella
AU - Meroni, Pier Luigi
AU - Ponticelli, Claudio
PY - 2004/1
Y1 - 2004/1
N2 - Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.
AB - Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.
KW - Antiphospholipid (aPL) antibodies
KW - Arterial hypertension
KW - Chronic renal insufficiency
KW - Fetal loss
KW - Lupus nephritis
KW - Systemic lupus erythematosus (SLE)
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=9144234103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144234103&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2003.09.011
DO - 10.1053/j.ajkd.2003.09.011
M3 - Article
C2 - 14712424
AN - SCOPUS:9144234103
VL - 43
SP - 28
EP - 36
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
IS - 1
ER -